Related Experiment Video

Updated: Jun 1, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Sonia Singh1, Diana Bradford1, Somak Chatterjee1

  • 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 14, 2025
PubMed

Insights

Tovorafenib is a new treatment for children with relapsed or refractory pediatric low-grade glioma (pLGG) who have specific BRAF alterations. This FDA-approved therapy shows significant response rates and duration in clinical trials.

Area of Science:

  • Pediatric Oncology
  • Molecular Targeted Therapy
  • RAF Kinase Inhibition

Background:

  • Pediatric low-grade glioma (pLGG) is a challenging diagnosis in young patients.
  • Limited systemic therapy options exist for relapsed or refractory pLGG with BRAF alterations.
  • Tovorafenib targets specific BRAF fusions, rearrangements, or V600 mutations.

Purpose of the Study:

  • To evaluate the efficacy and safety of tovorafenib in patients with relapsed or refractory pLGG.
  • To assess the overall response rate and duration of response to tovorafenib.
  • To support the FDA's accelerated approval of tovorafenib for this patient population.

Main Methods:

  • FIREFLY-1 trial: a single-arm, open-label, multicenter study.
  • Enrolled patients aged 6 months to 25 years with relapsed/refractory pLGG and activating BRAF alterations.
  • Primary endpoint: radiologic overall response rate by blinded independent central review.

Main Results:

  • Overall response rate was 51% (95% CI, 40-63) in 76 patients.
  • Median duration of response was 13.8 months (95% CI, 11.3-not estimable).
  • Represents the first FDA approval of a systemic therapy for pLGG with BRAF fusions/rearrangements.

Conclusions:

  • Tovorafenib demonstrates significant efficacy in treating relapsed or refractory pediatric low-grade glioma with BRAF alterations.
  • Accelerated FDA approval offers a new therapeutic option for this specific patient group.
  • Ongoing trials will further confirm the long-term benefits of tovorafenib.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...